Objectives: Patients with epilepsy and refractory comorbid psychiatric disorders often experience functional impairments and a lower quality of life as well as showing a lack of compliance with anti-epileptic medication regimens. We reasoned that widespread clinical benefits could be gained if the psychiatric comorbidities among these patients were reduced. In this study, we assessed the utility of anterior capsulotomy in managing medication-refractory comorbid psychotic symptoms and aggression in patients with epilepsy.
| INTRODUC TI ON
Epilepsy encompasses a group of different syndromes characterized by recurrent unprovoked seizures. This neurological disease is relatively common, afflicting at least 70 million people in the world. 1, 2 Epilepsy is complex in its etiology and clinical manifestations. 3 Compared to the general population, patients with epilepsy have a higher risk for suicidal ideation and psychiatric disorders. 4, 5 In particular, it is estimated that about 46% of patients with epilepsy has a comorbid anxiety disorder. Moreover, about 25% of epilepsy patients suffers from depression, 6, 7 and 5%-14% attempts or commits suicide. 8 Additionally, 4%-38% patients with epilepsy displays psychotic symptoms either with or without aggression. 9 The presence of psychiatric comorbidities among patients with epilepsy poses a major clinical challenge because it adversely affects the patients'
general functioning and quality of life, as well as their compliance with anti-epileptic medication regimens and other therapeutic interventions.
Patients with epilepsy who also present with psychotic symptoms and aggression represent a particularly challenging patient group to treat and care for. First, these patients typically receive antipsychotic medications to alleviate the comorbid "positive" (eg, delusions, hallucinations) and "negative" (eg, apathy, blunted affect) symptoms of schizophrenia. Antipsychotic medications, however, may not always be effective and may even exacerbate seizure frequency and severity. 10 Second, due to the nature of their psychiatric comorbidities, these patients often fail to comply with prescribed anti-epileptic medication regimens. This lack of compliance also applies to other therapeutic interventions offered, including neurophysiologic (eg, EEG, MEG, MRI) assessments required for seizure monitoring or surgery. Thus, the presence of severe medication-refractory psychiatric comorbidities can greatly disrupt epilepsy treatment for this group of patients. In the present study, we assessed the utility of anterior capsulotomy in improving their mental health status and compliance with anti-epileptic medication regimens.
Anterior capsulotomy was first introduced by Talairach, and refined by Leksell for treating various psychiatric diseases in the early 1950s. 11, 12 Since then, anterior capsulotomy has been mainly applied to the treatment of severe cases of refractory obsessive-compulsive disorder. 13 In recent years, however, anterior capsulotomy has also been applied successfully to the treatment of other psychiatric disorders, including depression 14 and schizophrenia. 15 Accordingly, in this retrospective case series we assessed the utility of anterior capsulotomy in managing refractory comorbid psychotic symptoms and aggression in several patients with epilepsy. Additionally, we examined the effects of anterior capsulotomy on patients' psychosocial function and quality of life. We hypothesized that anterior capsulotomy could be effective in improving both the patients' mental health status and their compliance with anti-epileptic medication regimens. 
| MATERIAL S AND ME THODS

| Participants
| Criteria for surgery
Patients who underwent the operation all satisfied the following cri- 
| Clinical outcome assessment
Each patient was clinically evaluated by a neurologist and a psychia- 
| Surgical procedure
The capsulotomy procedure used in this study followed the protocol described by Loughman et al 16 
| Drug therapy
All patients were treated with conventional AEDs. All patients except one also took antipsychotic medications (Table 1) . Dose and type of AEDs were not adjusted after surgery. The dose of postoperative psychiatric drugs was tapered gradually according to patient remission status; the psychiatric status of some patients improved to such an extent that they no longer needed medication.
| Statistical analysis
Firstly, we used Kolmogorov-Smirnov tests for normality. These tests were not significant (P > 0.05), indicating that the outcome variables did not deviate significantly from normality and that the relationships between the variables were homoscedastic. Subsequently, we performed several one-way repeated-measures multivariate analyses of variance, including time as a within-subjects factor (five levels: baseline, 1-week, 6-month, 12-month, last follow-up), to assess whether significant differences in the outcome measures existed between the five periods. Follow-up pairwise comparisons, using post hoc Bonferroni-corrected paired-samples t-tests, were employed to determine whether the outcome measures at baseline were significantly different from those at the three follow-up periods. For the QOLIE-31 data, we used Wilcoxon signed-ranks tests to compare the patients' quality of life data before and after surgery.
All statistical analyses were performed using IBM SPSS (version 23).
| RE SULTS
| Psychotic symptoms
After surgery, the severity of both positive symptoms and negative symptoms, as indexed by the PANSS scale scores, was significantly reduced among the patients with epilepsy (Table 2, Figure 2 ). For example, the positive scale score was improved by 56% and the negative scale score improved by 51% within 6 months after surgery. After 6 months, both types of psychotic symptoms continued to improve, though at a much slower rate, across the follow-up assessments. At the final follow-up, positive and negative symptoms were improved by, respectively, 64% and 59% relative to baseline.
| Impulsivity and aggression
Similarly, patients exhibited a significant reduction in their level of impulsivity, as measured by the BIS-11, across the follow-up periods (Table 2, Figure 3 ). As indexed by the BIS-11 subscale scores, all three aspects of impulsivity were substantially improved following surgery.
Although not formally tested, the motor aspect exhibited a larger improvement than the other aspects of impulsivity. For example, within 6 months after surgery, the patients' levels of motor impulsiveness, cognitive impulsiveness, and no-planning impulsiveness were reduced by 89%, 75%, and 68%, respectively. After 6 months, the levels of impulsivity remained relatively stable across the follow-up periods.
The patients' level of aggressiveness, assessed by the Buss-Perry Scale, was also significantly reduced after surgery (Table 2, Figure 4) .
However, the reduction of aggression was smaller than the reduction of impulsivity following surgery. For example, at 6-month follow-up, the patients' level of aggression was reduced by 34% relative to baseline level. After 6 months, aggression levels did not further change over the follow-up periods.
| Social function and quality of life
After surgery, the patients' social functioning, as measured by the SDSS, was significantly improved. Social function improved within a week and continued to improve until 6 months, reaching a plateau thereafter (Table 1, Figure 5 ). Furthermore, all aspects of the patients' quality of life, as indexed by the QoLIE-31 subscale scores,
showed marked improvements at 1-year follow-up (Figures 2-6 ). TA B L E 2 Clinical assessments of patients (N = 13) before and after surgery 
| Complications and side effects
Fatigue and laziness were the most common side effects. However, these side effects were transient and disappeared within 1-4 weeks.
As observed in other studies, 13, 17, 18 a few patients experienced headache, postoperative confusion, transient memory deficits, or weight gain following surgery. No intracranial hemorrhage or longterm or fatal complications occurred during the study.
| D ISCUSS I ON
In this study, we explored the utility of bilateral anterior capsulotomy in managing severe psychiatric comorbidities in patients with epilepsy.
After anterior capsulotomy, patients displayed significant improvements of psychotic symptoms, as well as reduced levels of impulsivity and aggression, along with improvements of social function and quality of life. These clinical benefits were evident within six months after surgery and remained stable or continued to improve at a slower rate thereafter. Furthermore, no significant side effects or complications occurred during the surgery and follow-up period. Accordingly, it seems that anterior capsulotomy can offer a safe and effective treatment for epilepsy patients with otherwise intractable psychiatric comorbidities. Anterior capsulotomy was associated with marked improvements of the patients' comorbid psychotic symptoms and aggression. This finding substantiates the results of a recent study of patients with schizophrenia. 15 Although little is known about the neurobiological mechanisms through which anterior capsulotomy produces its clinical effects, it may be hypothesized that this neurosurgical treatment, similar to antipsychotic medications, can resolve abnormal dopaminergic neurotransmission in the striatum, which mediates the positive symptoms of schizophrenia. 19, 20 In this view, anterior capsulotomy may act not only to restore function of diencephalic and limbic circuits involved in the initiation of emotional responses, such as fear and rage. But anterior capsulotomy may also recover frontal lobe functions that mediate higher cognitive functions and behavioral control. 21 Regardless of the precise mechanisms involved, it seems that anterior capsulotomy may have a role to play in the treatment of schizophrenia and related psychotic disorders.
However, to date, only some but not all studies have reported that anterior capsulotomy is an effective treatment for schizophrenia. 22 Furthermore, in contrast to pharmacotherapy, anterior capsulotomy is irreversible and a treatment option for only the most severe and otherwise intractable cases.
Finally, we observed that large individual patient differences existed in the clinical response to anterior capsulotomy. For example, the frequency of seizures declined in 11 patients after surgery, but two patients showed no clinical response. These two patients displayed a clinically meaningful response only after having received a second anterior capsulotomy a few years later. It turned out that these patients exhibited more severe psychiatric comorbidity than the other patients at the time of the first surgery, which apparently affected their clinical response to the surgery. Thus, due to large individual differences, a patient-and symptom-centered approach should be utilized to improve the clinical outcome of anterior capsulotomy.
| CON CLUS ION
Anterior capsulotomy seems to be an effective treatment for epilepsy patients with otherwise refractory psychotic symptoms and aggression. Moreover, this neurosurgical treatment seems to improve the patients' compliance with anti-epileptic medication regimens. However, given the relatively small patient sample and observational nature of the study, larger and well-controlled clinical trials are required before these conclusions can be accepted. 
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F I G U R E 6 Quality of Life in Epilepsy (QOLIE-31) subscale scores before surgery and one year after surgery. # indicates P = 0.02; *indicates P = 0.01; $ indicates P = 0.04, as assessed by using Wilcoxon signed-ranks test
